Gene therapy for Parkinson's disease

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Parkinson's disease is characterized by the degeneration of the nigrostriatal dopaminergic neurons with the manifestation of tremor, rigidity, akinesia, and disturbances of postural reflexes. Medication using L-DOPA and surgeries including deep brain stimulation are the established therapies for Parkinson's disease. Cell therapies are also effective and have rapidly developed with the recent advancement in molecular biological technology including gene transfer. In this review, ex vivo gene therapy using genetically engineered cell transplantation for Parkinson's disease model of animals is described, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as well as in vivo gene therapy using direct injection of viral vector to increase dopamine-production, ameliorate the survival of dopaminergic neurons, correct the deteriorated microenvironment, or normalize genetic abnormality. Furthermore, the future directions for clinical application are described together with recent clinical trials of gene therapy.

Original languageEnglish
Pages (from-to)301-309
Number of pages9
JournalJournal of Neural Transmission, Supplementa
Issue number73
DOIs
Publication statusPublished - 2009

Fingerprint

Genetic Therapy
Parkinson Disease
Dopaminergic Neurons
Cell Transplantation
Deep Brain Stimulation
Nerve Growth Factors
Tremor
Cell- and Tissue-Based Therapy
Catecholamines
Reflex
Dopamine
Animal Models
Clinical Trials
Technology
Injections
Genes
Therapeutics
Direction compound

Keywords

  • Cell therapy
  • Dopaminergic neurons
  • Encapsulation
  • Neural stem cell
  • Neurotrophic factor
  • Viral vector

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Gene therapy for Parkinson's disease. / Yasuhara, Takao; Date, Isao.

In: Journal of Neural Transmission, Supplementa, No. 73, 2009, p. 301-309.

Research output: Contribution to journalArticle

@article{d5d87b8702fa49ff8edd9f556a00172b,
title = "Gene therapy for Parkinson's disease",
abstract = "Parkinson's disease is characterized by the degeneration of the nigrostriatal dopaminergic neurons with the manifestation of tremor, rigidity, akinesia, and disturbances of postural reflexes. Medication using L-DOPA and surgeries including deep brain stimulation are the established therapies for Parkinson's disease. Cell therapies are also effective and have rapidly developed with the recent advancement in molecular biological technology including gene transfer. In this review, ex vivo gene therapy using genetically engineered cell transplantation for Parkinson's disease model of animals is described, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as well as in vivo gene therapy using direct injection of viral vector to increase dopamine-production, ameliorate the survival of dopaminergic neurons, correct the deteriorated microenvironment, or normalize genetic abnormality. Furthermore, the future directions for clinical application are described together with recent clinical trials of gene therapy.",
keywords = "Cell therapy, Dopaminergic neurons, Encapsulation, Neural stem cell, Neurotrophic factor, Viral vector",
author = "Takao Yasuhara and Isao Date",
year = "2009",
doi = "10.1007/978-3-211-92660-4-25",
language = "English",
pages = "301--309",
journal = "Journal of Neural Transmission, Supplement",
issn = "0303-6995",
publisher = "Springer Wien",
number = "73",

}

TY - JOUR

T1 - Gene therapy for Parkinson's disease

AU - Yasuhara, Takao

AU - Date, Isao

PY - 2009

Y1 - 2009

N2 - Parkinson's disease is characterized by the degeneration of the nigrostriatal dopaminergic neurons with the manifestation of tremor, rigidity, akinesia, and disturbances of postural reflexes. Medication using L-DOPA and surgeries including deep brain stimulation are the established therapies for Parkinson's disease. Cell therapies are also effective and have rapidly developed with the recent advancement in molecular biological technology including gene transfer. In this review, ex vivo gene therapy using genetically engineered cell transplantation for Parkinson's disease model of animals is described, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as well as in vivo gene therapy using direct injection of viral vector to increase dopamine-production, ameliorate the survival of dopaminergic neurons, correct the deteriorated microenvironment, or normalize genetic abnormality. Furthermore, the future directions for clinical application are described together with recent clinical trials of gene therapy.

AB - Parkinson's disease is characterized by the degeneration of the nigrostriatal dopaminergic neurons with the manifestation of tremor, rigidity, akinesia, and disturbances of postural reflexes. Medication using L-DOPA and surgeries including deep brain stimulation are the established therapies for Parkinson's disease. Cell therapies are also effective and have rapidly developed with the recent advancement in molecular biological technology including gene transfer. In this review, ex vivo gene therapy using genetically engineered cell transplantation for Parkinson's disease model of animals is described, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as well as in vivo gene therapy using direct injection of viral vector to increase dopamine-production, ameliorate the survival of dopaminergic neurons, correct the deteriorated microenvironment, or normalize genetic abnormality. Furthermore, the future directions for clinical application are described together with recent clinical trials of gene therapy.

KW - Cell therapy

KW - Dopaminergic neurons

KW - Encapsulation

KW - Neural stem cell

KW - Neurotrophic factor

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=77952310482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952310482&partnerID=8YFLogxK

U2 - 10.1007/978-3-211-92660-4-25

DO - 10.1007/978-3-211-92660-4-25

M3 - Article

C2 - 20411788

AN - SCOPUS:77952310482

SP - 301

EP - 309

JO - Journal of Neural Transmission, Supplement

JF - Journal of Neural Transmission, Supplement

SN - 0303-6995

IS - 73

ER -